DCTHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
DELCATH SYSTEMS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$14.37+0.29 (+2.06%)
Close on Oct 19, 2026
- Market cap
- $571.37M
- P/E (TTM)
- 1437.0
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
50.2%
17M of 35M shares
Institutional holders
120
20 new, 20 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $287.46K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 6,719,993 | 9.90% | 13D (active) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 1,836,121 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Daniel Kaufman | 1,766,432 | 5.08% | 13G (passive) | Mar 18, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DCTH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3,300,389 | 9.51% | $41.55M | – | 15.44% |
| BlackRock, Inc. | 2,706,802 | 7.80% | $34.08M | +922,336 | 0.00% |
| Vanguard Capital Management LLC | 1,221,247 | 3.52% | $15.38M | −108,041 | 0.00% |
| Propel Bio Management, LLC | 871,460 | 2.51% | $10.97M | −108,238 | 5.74% |
| Geode Capital Management, LLC | 733,115 | 2.11% | $9.23M | +41,084 | 0.00% |
| State Street Corp | 679,280 | 1.96% | $8.55M | +14,852 | 0.00% |
| Algert Global LLC | 580,708 | 1.67% | $7.31M | +434,975 | 0.09% |
| Millennium Management LLC | 566,371 | 1.63% | $7.13M | −21,684 | 0.00% |
| Divisadero Street Capital Management, LP | 499,796 | 1.44% | $6.29M | – | 0.14% |
| Morgan Stanley | 407,983 | 1.18% | $5.14M | +22,459 | 0.00% |
| ExodusPoint Capital Management, LP | 359,884 | 1.04% | $4.53M | +323,916 | 0.03% |
| Private Wealth Advisors, LLC | 310,863 | 0.90% | $3.91M | −280,661 | 1.00% |
| Simplify Asset Management Inc. | 264,770 | 0.76% | $3.33M | +3,644 | 0.05% |
| Northern Trust Corp | 252,108 | 0.73% | $3.17M | +245 | 0.00% |
| Goldman Sachs Group Inc | 250,312 | 0.72% | $3.15M | −38,819 | 0.00% |
| ADAR1 Capital Management, LLC | 224,385 | 0.65% | $2.83M | – | 0.13% |
| Marshall Wace, Llp | 218,963 | 0.63% | $2.76M | +27,333 | 0.00% |
| Dimensional Fund Advisors LP | 210,298 | 0.61% | $2.65M | New | 0.00% |
| Kennedy Capital Management LLC | 204,143 | 0.59% | $2.57M | −3,780 | 0.05% |
| Vanguard Portfolio Management LLC | 193,448 | 0.56% | $2.44M | +15,412 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 120 | 17M | 50.2% | 20 / 48 | 26 / 20 | 3M | 2M |
| Q1 2026 | 121 | 16M | 47.0% | 27 / 37 | 36 / 23 | 4M | 3M |
| Q4 2025 | 119 | 17M | 49.4% | 18 / 42 | 36 / 19 | 2M | 3M |
| Q3 2025 | 124 | 18M | 52.1% | 31 / 39 | 36 / 24 | 4M | 4M |
| Q2 2025 | 117 | 18M | 52.9% | 49 / 39 | 19 / 29 | 7M | 4M |
| Q1 2025 | 98 | 15M | 43.5% | 20 / 41 | 26 / 12 | 5M | 4M |
| Q4 2024 | 90 | 14M | 39.4% | 30 / 33 | 13 / 8 | 5M | 1M |
| Q3 2024 | 69 | 10M | 30.0% | 23 / 17 | 14 / 5 | 2M | 2M |
| Q2 2024 | 52 | 10M | 30.2% | 19 / 17 | 10 / 3 | 3M | 2M |
| Q1 2024 | 36 | 9M | 24.8% | 2 / 13 | 12 / 8 | 3M | 1M |
| Q4 2023 | 42 | 7M | 19.9% | 11 / 19 | 5 / 7 | 3M | 4M |
| Q3 2023 | 38 | 7M | 20.4% | 11 / 12 | 8 / 4 | 3M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DCTH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 889,410 | 2.56% | $11.20M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 757,196 | 2.18% | $9.53M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 314,275 | 0.91% | $3.84M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 304,809 | 0.88% | $3.84M | 0.00% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 261,126 | 0.75% | $3.29M | 4.26% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 229,809 | 0.66% | $2.89M | 0.02% | Jun 30, 2026 |
| North Square Dynamic Small Cap Fund | 192,363 | 0.55% | $2.07M | 0.26% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 154,942 | 0.45% | $1.67M | 0.01% | May 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 141,229 | 0.41% | $1.78M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 140,170 | 0.40% | $1.51M | 0.00% | May 31, 2026 |
| Small Cap Equity Fund | 122,700 | 0.35% | $1.54M | 0.15% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 100,899 | 0.29% | $1.09M | 0.02% | May 29, 2026 |
| iShares Micro-Cap ETF | 96,698 | 0.28% | $1.22M | 0.08% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Growth Fund | 73,405 | 0.21% | $924.17K | 0.11% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 70,457 | 0.20% | $860.98K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gerard J. Michel | CHIEF EXECUTIVE OFFICER, Director | 342,034 | 0.99% | Mar 3, 2026 |
| Sandra Pennell | Chief Financial Officer | 77,018 | 0.22% | Mar 6, 2026 |
| Martha S. Rook | CHIEF OPERATING OFFICER | – | – | Feb 18, 2026 |
| Vojo Vukovic | CHIEF MEDICAL OFFICER | 168,882 | 0.49% | Feb 18, 2026 |
| David L. Hoffman | GEN'L COUNSEL, CCO & SECY | 74,330 | 0.21% | Feb 18, 2026 |
| Kevin Muir | GM INTERVENTIONAL ONCOLOGY | 18,582 | 0.05% | Feb 18, 2026 |
| Gil Aharon | Director | 4,483,178 | 12.92% | May 14, 2026 |
| Elizabeth Czerepak | Director | – | – | May 14, 2026 |
| John Richard Sylvester | Director | 14,936 | 0.04% | May 14, 2026 |
| Bridget A. Martell | Director | – | – | May 14, 2026 |
| Steven A. J. Salamon | Director | 4,534,493 | 13.07% | May 14, 2026 |
| Rosalind Advisors, Inc. | Director | 3,013,468 | 8.68% | May 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sandra Pennell Chief Financial Officer | Mar 6, 2026 | Buy | +5,533 | $9.04 | $50.02K | 77,018 |
| Gerard J. Michel CHIEF EXECUTIVE OFFICER, Director | Mar 2, 2026 | Buy | +11,200 | $8.96 | $100.35K | 342,034 |
| John Richard Sylvester Director | Nov 21, 2025 | Buy | +4,386 | $8.89 | $38.99K | 14,936 |
| Gerard J. Michel CHIEF EXECUTIVE OFFICER, Director | Nov 11, 2025 | Buy | +11,500 | $8.53 | $98.09K | 330,834 |
| Vojo Vukovic CHIEF MEDICAL OFFICER | Jun 12, 2025 | Option exercise | +42,000 | $4.78 | $200.76K | 168,882 |
| Gil Aharon Director | May 5, 2025 | Option exercise | +400,000 | $10.00 | $4.00M | 3,413,468 |
| Steven A. J. Salamon Director | May 5, 2025 | Option exercise | +400,000 | $10.00 | $4.00M | 3,413,468 |
| Steven A. J. Salamon Director | May 5, 2025 | Option exercise | +400,000 | $10.00 | $4.00M | 3,413,468 |
| Steven A. J. Salamon Director | Dec 24, 2024 | Conversion | +250,000 | $10.00 | $2.50M | 3,013,468 |
| Rosalind Advisors, Inc. Director | Dec 24, 2024 | Conversion | +250,000 | $10.00 | $2.50M | 3,013,468 |
| Gil Aharon Director | Dec 24, 2024 | Conversion | +250,000 | $10.00 | $2.50M | 3,013,468 |
| Gerard J. Michel CHIEF EXECUTIVE OFFICER, Director | Oct 22, 2024 | Option exercise | +16,666 | $6.00 | $100.00K | 319,334 |
| Gil Aharon Director | Apr 18, 2024 | Option exercise | +619,946 | $6199.46 | $3.84B | 2,681,271 |
| Gil Aharon Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,681,271 |
| Steven A. J. Salamon Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,732,586 |
| Steven A. J. Salamon Director | Apr 18, 2024 | Option exercise | +619,946 | $6199.46 | $3.84B | 2,732,586 |
| Steven A. J. Salamon Director | Apr 18, 2024 | Option exercise | +619,946 | $0.01 | $6.20K | 2,732,586 |
| Steven A. J. Salamon Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,732,586 |
| Gil Aharon Director | Apr 18, 2024 | Option exercise | +619,946 | $0.01 | $6.20K | 2,681,271 |
| Gil Aharon Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,681,271 |
| Gil Aharon Director | Apr 18, 2024 | Option exercise | +619,946 | $0.01 | $6.20K | 2,763,468 |
| Gil Aharon Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,763,468 |
| Rosalind Advisors, Inc. Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,763,468 |
| Rosalind Advisors, Inc. Director | Apr 18, 2024 | Option exercise | +619,946 | $6199.46 | $3.84B | 2,763,468 |
| Steven A. J. Salamon Director | Mar 19, 2024 | Buy | +26,882 | $3.72 | $100.00K | 1,121,025 |
| Gil Aharon Director | Mar 19, 2024 | Buy | +26,882 | $3.72 | $100.00K | 1,069,710 |
| Sandra Pennell SVP OF FINANCE, PFO AND PAO | Mar 19, 2024 | Award | +26,881 | $3.72 | $100.00K | 61,052 |
| Gerard J. Michel CHIEF EXECUTIVE OFFICER, Director | Mar 19, 2024 | Award | +40,323 | $3.72 | $150.00K | 302,668 |
| David L. Hoffman GEN'L COUNSEL, CCO & SECY | Mar 19, 2024 | Award | +20,161 | $3.72 | $75.00K | 74,330 |
| Vojo Vukovic CHIEF MEDICAL OFFICER | Mar 19, 2024 | Award | +26,882 | $3.72 | $100.00K | 126,882 |
| Kevin Muir GM INTERVENTIONAL ONCOLOGY | Mar 19, 2024 | Award | +13,441 | $3.72 | $50.00K | 18,582 |
| Vojo Vukovic Chief Medical Officer | Dec 12, 2023 | Buy | +40,000 | $3.00 | $120.00K | 100,000 |
| Gerard J. Michel Chief Executive Officer, Director | Dec 8, 2023 | Buy | +34,000 | $2.94 | $99.96K | 262,345 |
| Sandra Pennell SVP of Finance, PFO and PAO | Nov 17, 2023 | Buy | +30,000 | $2.43 | $72.90K | 30,000 |
| Rosalind Advisors, Inc. Director | Nov 17, 2023 | Buy | +100,000 | $2.40 | $240.00K | 1,038,828 |
| David L. Hoffman See Remarks | Nov 16, 2023 | Buy | +40,000 | $2.48 | $99.20K | 40,000 |
| Vojo Vukovic Chief Medical Officer | Nov 16, 2023 | Buy | +60,000 | $2.48 | $148.80K | 60,000 |
| John Purpura Chief Operating Officer | Oct 13, 2023 | Buy | +14,505 | $3.44 | $49.90K | 41,526 |
| John Richard Sylvester Director | Aug 21, 2023 | Buy | +10,550 | $4.80 | $50.64K | 10,550 |
| Gerard J. Michel Chief Executive Officer, Director | Aug 18, 2023 | Option exercise | +31,110 | $4.50 | $140.00K | 228,345 |
| Gerard J. Michel Chief Executive Officer, Director | Mar 29, 2023 | Buy | +19,646 | $4.84 | $95.09K | 197,235 |
| Steven A. J. Salamon Director | Dec 14, 2022 | Buy | +15,215 | $3.62 | $55.08K | 455,315 |
| Rosalind Advisors, Inc. Director | Dec 14, 2022 | Buy | +15,215 | $3.62 | $55.08K | 459,315 |
| Gerard J. Michel Chief Executive Officer, Director | Dec 13, 2022 | Buy | +51,725 | $2.90 | $150.00K | 177,589 |
| Gerard J. Michel Chief Executive Officer, Director | Jul 20, 2022 | Buy | +62,814 | $3.98 | $250.00K | 125,864 |
| John Purpura Chief Operating Officer | May 16, 2022 | Buy | +3,300 | $4.61 | $15.21K | 27,021 |
| Steven A. J. Salamon Director | May 13, 2022 | Buy | +5,000 | $5.03 | $25.15K | 440,100 |
| Steven A. J. Salamon Director | May 12, 2022 | Buy | +6,000 | $4.90 | $29.40K | 29,424 |
| Rosalind Advisors, Inc. Director | Apr 19, 2022 | Buy | +1,600 | $6.25 | $10.00K | 433,100 |
| Steven A. J. Salamon Director | Apr 19, 2022 | Buy | +1,600 | $6.25 | $10.00K | 429,100 |
| Gil Aharon Director | Apr 18, 2022 | Buy | +2,000 | $6.35 | $12.70K | 404,000 |
| Rosalind Advisors, Inc. Director | Apr 18, 2022 | Buy | +2,000 | $6.35 | $12.70K | 431,500 |
| Gerard J. Michel See Remarks, Director | Apr 18, 2022 | Buy | +1,800 | $6.37 | $11.47K | 63,050 |
| Gerard J. Michel See Remarks, Director | Apr 18, 2022 | Buy | +200 | $6.34 | $1.27K | 61,250 |
| Steven A. J. Salamon Director | Apr 13, 2022 | Buy | +1,500 | $6.45 | $9.68K | 427,500 |
| Rosalind Advisors, Inc. Director | Apr 13, 2022 | Buy | +1,500 | $6.45 | $9.68K | 429,500 |
| Steven A. J. Salamon Director | Apr 12, 2022 | Buy | +2,500 | $6.48 | $16.20K | 425,000 |
| Rosalind Advisors, Inc. Director | Apr 12, 2022 | Buy | +2,500 | $6.48 | $16.20K | 428,000 |
| John Purpura Chief Operating Officer | Apr 11, 2022 | Buy | +5,000 | $6.59 | $32.95K | 23,721 |
| Gerard J. Michel See Remarks, Director | Apr 8, 2022 | Buy | +1,000 | $6.55 | $6.55K | 61,050 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Roger G. Stoll Phd Retired | Jul 9, 2024 | 1,000 | $7.29K | Jul 9, 2024 | Stock Options |